Bosch Business Innovations will invest €200m over five years, targeting startups in health, software-defined manufacturing, and carbon capture, with outside founders brought in at the pre-seed stage.
The initiative leverages Bosch’s industrial capabilities, research, and global supply chains, aiming to commercialise remote health monitoring, industrial software platforms, and carbon capture technologies.
This move reflects a broader corporate shift toward in-house venture building for innovation control, as traditional corporate venture capital models face scrutiny over their strategic effectiveness.
How might Bosch’s venture studio approach impact traditional suppliers and partners in its core industries?
As Bosch spins out startups, what happens if a venture’s technology outpaces Bosch’s own core business or strategy?
What lessons can other R&D-heavy companies draw from Bosch’s shift to venture studios, and are there pitfalls they should avoid?
Will Bosch’s heavy investment in AI and hydrogen put it ahead of rivals, or are there risks of overconcentration in unproven markets?
What criteria will Bosch use to select which deep tech ideas or founders receive backing, and how transparent is this process?
Could the focus on recurring asset-backed revenue reshape how investors value deep tech startups emerging from corporate studios?